ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Verastem (VSTM)
Verastem stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$10.10▲ +1.00%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
45%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Verastem in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Verastem
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Verastem a 45% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $8.46 and $11.44; in 9 out of 10, between $6.47 and $14.96. Estimated annual volatility is 90%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $697M
- 52-week high
- $10.82
- 52-week low
- $3.43
- Revenue (12 months)
- $87.5M
- Revenue growth (YoY)
- +209.1%
- Gross margin
- 82.9%
- Return on equity
- -471.2%
- Free cash flow (12 months)
- $-103M
- Beta
- 0.32
What this means
ATLAS does not publish a fair value for VSTM right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks VSTM has traded between $3.43 and $10.82. Today it is 6.7% below that high and 194% above its low.
Its beta is 0.32: it tends to move less than the market.
About the company
Verastem Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer, with an emphasis on tumors driven by the RAS/MAPK signaling pathway.
Want to see everything about Verastem?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Verastem do?
Verastem Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer, with an emphasis on tumors driven by the RAS/MAPK signaling pathway.
What is the chance VSTM goes up next month?
45%: close to a coin flip. In half of the simulated outcomes, VSTM ends the month between $8.46 and $11.44.
How big is Verastem and what is its P/E ratio?
Verastem's market capitalization is $697M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is VSTM?
ATLAS estimates annual volatility at 90%. In a typical month, half of the outcomes end between $8.46 and $11.44.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer